Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax

---
identifier: "/us/fr/02-11072"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax"
title_number: 0
title_name: "Federal Register"
section_number: "02-11072"
section_name: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax"
positive_law: false
currency: "2002-05-03"
last_updated: "2002-05-03"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "02-11072"
document_type: "notice"
publication_date: "2002-05-03"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "67 FR 22414"
fr_volume: 67
fr_action: "Notice."
---


#  Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Application Concerning a Method of Making a Vaccine for Anthrax

**AGENCY:**

Department of the Army, DoD.

**ACTION:**

Notice.

**SUMMARY:**

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of U.S. Patent Application Serial No. 09/520,215 entitled “Method of Making a Vaccine for Anthrax,” filed March 7, 2000. The United States Government, as represented by the Secretary of the Army has rights in this invention.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, both at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

A method of making a vaccine from a protective antigen. The protective antigen is useful against Bacillus anthracis. The protective antigen is produced by an asporogenic organism, which overproduces the desired antigen. The asporogenic organism is a recombinant asporogenic B. anthracis. The recombinant asporogenic *B. anthracis* was derived from a Δ Sterne-1(pPA102) strain of bacteria and binds to dye when grown on Congo Red Agar.

Luz D. Ortiz,

Army Federal Register Liaison Officer.